Skip to Main content Skip to Navigation
Journal articles

Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques

Abstract : In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of “tumor markers”. Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. Despite their limited utility for screening and diagnosis, conventional tumor markers remain interesting for evaluation of prognoses, the choice and optimization of treatments, as well as for monitoring the effectiveness of those treatments. In this article, we revisit the conventional serum markers that are enjoying a ‘come back’ thanks to the development of high-performance scores based on biological, cytological, clinical, or radiological criteria.
Document type :
Journal articles
Complete list of metadata

https://hal.sorbonne-universite.fr/hal-03525850
Contributor : Hal Sorbonne Université Gestionnaire Connect in order to contact the contributor
Submitted on : Friday, January 14, 2022 - 10:09:43 AM
Last modification on : Sunday, January 16, 2022 - 3:06:43 AM

File

1-s2.0-S0007455121005749-main....
Publication funded by an institution

Identifiers

Citation

Alexandre Perrier, Pierre Hainaut, Pierre-Jean Lamy, Alexandre Guenoun, Dinh-Phong Nguyen, et al.. Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques. Bulletin du Cancer, John Libbey Eurotext, 2022, ⟨10.1016/j.bulcan.2021.11.010⟩. ⟨hal-03525850⟩

Share

Metrics

Les métriques sont temporairement indisponibles